ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 101,16
-0,06%
Dow Jones
38 503,69
0,69%
DAX
18 202,57
0,33%
Brent Oil
87,585
0,02%
Bitcoin
66 660,71
0,38%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. Oragenics Inc (OGEN)

  7. Oragenics Inc (OGEN) Actualités

OGEN Oragenics Inc

1,09
0,00 (0,00%)
24 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Oragenics Inc OGEN AMEX Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 1,09 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,09
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
19/4/202423:50BWOragenics, Inc. Announces Notification of Noncompliance with..
01/4/202415:05BWOragenics, Inc. Files 10K and Provides Company Update
18/3/202412:00BWOragenics Appoints James Kelly MD, Chief Medical Officer, to..
06/3/202422:24EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/3/202413:45BWOragenics, Inc. Prepares Drug for Phase II Clinical Trials..
01/3/202422:04BWOragenics Announces Closing of Public Offering
29/2/202422:41EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/2/202415:03EDGAR2Form 8-K - Current report
28/2/202403:25BWOragenics Announces Pricing of Public Offering
27/2/202423:09EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
27/2/202423:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
27/2/202422:33BWOragenics Announces Proposed Public Offering
13/2/202402:06EDGAR2Form SC 13D - General statement of acquisition of beneficial..
12/2/202422:45EDGAR2Form 8-K - Current report
12/2/202422:41BWOragenics, Inc. Announces Leadership Transition
07/2/202414:00EDGAR2Form 8-K - Current report
07/2/202414:00BWOragenics, Inc. Announces Expiration of Its Investment..
05/2/202414:00EDGAR2Form 8-K - Current report
05/2/202414:00BWOragenics, Inc. Preparing for Phase II Clinical Trials to..
23/1/202423:34BWOragenics Announces Termination of At-The-Market Offering..
23/1/202423:18EDGAR2Form 8-K - Current report
22/1/202423:30EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
16/1/202415:10EDGAR2Form 8-K - Current report
16/1/202415:08EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
16/1/202415:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/1/202422:37EDGAR2Form S-8 - Securities to be offered to employees in employee..
02/1/202423:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202415:22EDGAR2Form 8-K - Current report
02/1/202413:30BWOragenics Completes Acquisition of Odyssey Health’s..
29/12/202313:30EDGAR2Form 8-K - Current report
15/12/202321:45EDGAR2Form 8-K - Current report
08/12/202322:00EDGAR2Form 8-K - Current report
01/12/202323:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202323:50EDGAR2Form 144 - Report of proposed sale of securities
20/11/202321:45EDGAR2Form 8-K - Current report
16/11/202320:37EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
02/11/202312:00EDGAR2Form 8-K - Current report
02/11/202312:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
02/11/202312:00BWOragenics Issues Update to Shareholders
30/10/202321:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
30/10/202321:00EDGAR2Form DEF 14A - Other definitive proxy statements
18/10/202314:30BWOragenics Announces Appointment of Bruce Cassidy and John..
06/10/202322:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202322:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202322:28EDGAR2Form 3 - Initial statement of beneficial ownership of..
06/10/202322:25EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/10/202323:29EDGAR2Form 8-K - Current report
05/10/202312:30EDGAR2Form 8-K - Current report
05/10/202312:30BWOragenics to Acquire Odyssey Health’s Neurological Drug..
29/9/202322:00EDGAR2Form 8-K - Current report

Dernières Valeurs Consultées

AMEX
OGEN
Oragenics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés